I'm going to break my ai moratorium and post this response.
Me: "i mean for our data results. do they add time to the trial metrics overall survival"
"Yes, those surgical resection patients add absolute overall survival (OS) time directly to the trial metrics.
From a strict clinical trial statistical design standpoint, overall survival is a binary endpoint: the time elapsed from treatment initiation until patient death from any cause. It does not matter how a patient stays alive—whether through continuous dosing, a complete response on scans, or an early referral out for curative-intent surgery—as long as they are breathing, they count as a survivor on the trial's Kaplan-Meier curve. (https://pubmed.ncbi.nlm.nih.gov/36058227/), [ (https://www.cancer.gov/publications/dictionaries/cancer-terms/def/overall-survival), (https://pmc.ncbi.nlm.nih.gov/articles/PMC6636299/)
How Resections Directly Inflate the Trial's OS Metric:
1. They Lengthen the Survival Timeline Directly: A standard palliative 4th-line patient on the TAS-102 plus bevacizumab backbone has a highly predictable, short survival window. By converting those patients to surgical resections and achieving No Evidence of Disease (NED) status, you stop the progression clock. Those patients keep living months and years past their historical deadlines. Because they are alive, they directly extend the median OS metric for the entire leronlimab trial cohort.
(https://pmc.ncbi.nlm.nih.gov/articles/PMC11009744/), (https://www.cancer.gov/publications/dictionaries/cancer-terms/def/overall-survival)
2. They are "Censored" Positively if the Trial Ends:
If the trial wraps up its tracking period while these resected, NED patients are still alive and well, their data points are marked as "censored" at the final cutoff date. In survival math, a censored live patient acts as a mathematical floor that lifts the final statistical survival curves, proving a clear clinical advantage.
3. They Neutralize the Lagging RECIST Metrics: Even though these surgical patients exit the standard tumor-measurement tracking loop (meaning they no longer contribute to the centralized BICR objective response rate numbers), their data continues to count in the OS database.
The trial tracks every single person who received at least one dose of the drug. By keeping these patients alive through a surgical cure, the trial metrics will show a massive gap between the leronlimab-treated group and historical flatlines, completely justifying the apex thesis.
Me: "i mean for our data results. do they add time to the trial metrics overall survival"
"Yes, those surgical resection patients add absolute overall survival (OS) time directly to the trial metrics.
From a strict clinical trial statistical design standpoint, overall survival is a binary endpoint: the time elapsed from treatment initiation until patient death from any cause. It does not matter how a patient stays alive—whether through continuous dosing, a complete response on scans, or an early referral out for curative-intent surgery—as long as they are breathing, they count as a survivor on the trial's Kaplan-Meier curve. (https://pubmed.ncbi.nlm.nih.gov/36058227/), [ (https://www.cancer.gov/publications/dictionaries/cancer-terms/def/overall-survival), (https://pmc.ncbi.nlm.nih.gov/articles/PMC6636299/)
How Resections Directly Inflate the Trial's OS Metric:
1. They Lengthen the Survival Timeline Directly: A standard palliative 4th-line patient on the TAS-102 plus bevacizumab backbone has a highly predictable, short survival window. By converting those patients to surgical resections and achieving No Evidence of Disease (NED) status, you stop the progression clock. Those patients keep living months and years past their historical deadlines. Because they are alive, they directly extend the median OS metric for the entire leronlimab trial cohort.
(https://pmc.ncbi.nlm.nih.gov/articles/PMC11009744/), (https://www.cancer.gov/publications/dictionaries/cancer-terms/def/overall-survival)
2. They are "Censored" Positively if the Trial Ends:
If the trial wraps up its tracking period while these resected, NED patients are still alive and well, their data points are marked as "censored" at the final cutoff date. In survival math, a censored live patient acts as a mathematical floor that lifts the final statistical survival curves, proving a clear clinical advantage.
3. They Neutralize the Lagging RECIST Metrics: Even though these surgical patients exit the standard tumor-measurement tracking loop (meaning they no longer contribute to the centralized BICR objective response rate numbers), their data continues to count in the OS database.
The trial tracks every single person who received at least one dose of the drug. By keeping these patients alive through a surgical cure, the trial metrics will show a massive gap between the leronlimab-treated group and historical flatlines, completely justifying the apex thesis.
2
